Leonardo A. Meza-Zepeda
Universitetet i Oslo
H-index: 48
Europe-Norway
Top articles of Leonardo A. Meza-Zepeda
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma | Nature Communications | Yang Zhou Partho Sarothi Ray Jianguo Zhu Frank Stein Mandy Rettel | 2024/4/1 |
Evolutionary mode and timing of dissemination of high-grade serous carcinomas | JCI insight | Anita Sveen Bjarne Johannessen Solveig MK Klokkerud Sigrid M Kraggerud Leonardo A Meza-Zepeda | 2024/2/8 |
Chromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential | Molecular Oncology | Heidi Maria Namløs Ksenia Khelik Sigve Nakken Daniel Vodák Eivind Hovig | 2023/11 |
213P Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway | Annals of Oncology | HEG Russnes HL Nilsen M Jebens E Janssen RM Wold | 2023/10/1 |
The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition | Frontiers in immunology | Irantzu Anzar Brandon Malone Pubudu Samarakoon Ioannis Vardaxis Boris Simovski | 2023/9/20 |
Sex differences in localized gastrointestinal stromal tumor. | Kjetil Boye Ivar Hompland Jeanne-Marie Berner Leonardo A Meza-Zepeda Toto Hølmebakk | 2023/6/1 | |
Heritable defects in telomere and mitotic function selectively predispose to sarcomas | Science | Mandy L Ballinger Swetansu Pattnaik Piyushkumar A Mundra Milita Zaheed Emma Rath | 2023/1/20 |
A national precision cancer medicine implementation initiative for Norway | Nature Medicine | Kjetil Taskén Hege EG Russnes Eline Aas Line Bjørge Egil S Blix | 2022/5 |
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma | British Journal of Cancer | Elisa Fiorito Patrycja Szybowska Ellen M Haugsten Michal Kostas Geir F Øy | 2022/11/23 |
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour | British journal of cancer | Tatiana Georgiesh Ninna Aggerholm-Pedersen Patrick Schöffski Yifan Zhang Andrea Napolitano | 2022/11/9 |
miR-486-5p expression is regulated by DNA methylation in osteosarcoma | BMC genomics | Heidi M Namløs Magne Skårn Deeqa Ahmed Iwona Grad Kim Andresen | 2022/2/17 |
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy | Genome Medicine | Andreas Venizelos Christina Engebrethsen Wei Deng Jürgen Geisler Stephanie Geisler | 2022/8/11 |
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence | Leukemia | Kristine Misund Davine Hofste Op Bruinink Eivind Coward Remco M Hoogenboezem Even Holth Rustad | 2022/7 |
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway | Journal of translational medicine | Åslaug Helland Hege G Russnes Gro Live Fagereng Khalid Al-Shibli Yvonne Andersson | 2022/5/14 |
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines | Frontiers in Oncology | Mariaserena Giliberto Leonardo Miranda Santana Toril Holien Kristine Misund Sigve Nakken | 2022/11/29 |
Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour | Pathology | Tatiana Georgiesh Heidi Maria Namløs Nitin Sharma Susanne Lorenz Ola Myklebost | 2021/10/1 |
Integrating anatomical, molecular and clinical risk factors in gastrointestinal stromal tumor of the stomach | Annals of Surgical Oncology | Toto Hølmebakk Anne Marit Wiedswang Leonardo A Meza-Zepeda Ivar Hompland Ingvild VK Lobmaier | 2021/10/1 |
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial | Cancer Immunology, Immunotherapy | Kjetil Boye Alessandra Longhi Tormod Guren Susanne Lorenz Stine Næss | 2021/9 |
Rapid genome editing by CRISPR-Cas9-POLD3 fusion | Elife | Ganna Reint Zhuokun Li Kornel Labun Salla Keskitalo Inkeri Soppa | 2021/12/13 |
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening | Plos one | Iwona Grad Robert Hanes Pilar Ayuda-Durán Marieke Lydia Kuijjer Jorrit M Enserink | 2021/3/10 |
